Results continue to suggest urgent need for new therapies in MoCD Type A, with median survival of <4 years and rapid disease onset within the first month of life for most patients Continue to ...
(RTTNews) - BridgeBio Pharma Inc. (BBIO) and Sentynl Therapeutics Inc., on Tuesday, announced that the European Commission has granted marketing authorization for NULIBRY for the treatment of patients ...
Early administration of the drug Fosdenopterin/rcPMP improves the chances of survival of infants with MoCD type A and promotes the development of brain functions. The drug fosdenopterin/rcPMP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback